<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623814</url>
  </required_header>
  <id_info>
    <org_study_id>HEC113995-P-04/CRC-C2006</org_study_id>
    <nct_id>NCT04623814</nct_id>
  </id_info>
  <brief_title>the Safety, Tolerability, and Pharmacokinetics Study of HEC113995</brief_title>
  <official_title>HEC113995-A Phase I,Double-Blind, Placebo-Controlled, Multiple Oral Dose, Safety, Tolerability, Pharmacokinetics and Food Effect Study in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC113995 PA•H2O in Healthy&#xD;
      Subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2020</start_date>
  <completion_date type="Actual">August 12, 2020</completion_date>
  <primary_completion_date type="Actual">August 12, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event</measure>
    <time_frame>up to 34 days</time_frame>
    <description>To assess the safety and tolerability of therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve (AUC) from time zero to infinity(AUC0-∞ )</measure>
    <time_frame>up to 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration （ Cmax）</measure>
    <time_frame>up to 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak（tmax）</measure>
    <time_frame>up to 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal elimination half-life（t½）</measure>
    <time_frame>up to 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution（Vz/F）</measure>
    <time_frame>up to 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Residence Time（ MRT）</measure>
    <time_frame>up to 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Apparent Clearance （CL/F）</measure>
    <time_frame>up to 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Accumulation Ratio（R）</measure>
    <time_frame>up to 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Effect on the Cmax</measure>
    <time_frame>up to 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Effect on the AUC</measure>
    <time_frame>up to 120 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Food effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HEC113995 20mg will be administered fasted, with regular meal or with high-fat meal for once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Doses-HEC113995 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HEC113995 10mg will be administered fasted for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Doses-HEC113995 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HEC113995 20mg will be administered with food for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Doses-HEC113995 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HEC113995 40mg will be administered with food for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Doses-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arms will be administered fasted or with food for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Food</intervention_name>
    <description>HEC113995 20mg will be taken orally fasted or with food</description>
    <arm_group_label>Food effect</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC113995</intervention_name>
    <description>HEC113995 will be taken orally fasted (HEC113995 10mg）or with food (HEC113995 20mg and 40mg） for 10 days</description>
    <arm_group_label>Multiple Ascending Doses-HEC113995 10mg</arm_group_label>
    <arm_group_label>Multiple Ascending Doses-HEC113995 20mg</arm_group_label>
    <arm_group_label>Multiple Ascending Doses-HEC113995 40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>The placebo will be administered fasted or with food for 10 days.</description>
    <arm_group_label>Multiple Ascending Doses-placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Subjects who are willing and are able to provide a written informed consent to&#xD;
             participate in the study.&#xD;
&#xD;
          -  2. Without Plan for pregnancy or pregnant within 3 months after enrollment throughout&#xD;
             the trial.&#xD;
&#xD;
          -  3. Subjects aged between 18 and 45 (both inclusive) years old.&#xD;
&#xD;
          -  4. Healthy volunteers has a body weight ≥50 kg (for male) or ≥ 45kg (for female) and&#xD;
             body mass index ≥18 and ≤28 kg/m2 at screening.&#xD;
&#xD;
          -  5. Subjects, who are healthy, as having no clinically significant abnormalities in&#xD;
             vital signs, physical examination, clinical laboratory test results, Chest X-ray and&#xD;
             12-lead electrocardiogram (ECG).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Subjects with a positive serology for human immunodeficiency virus (HIV)&#xD;
             antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies&#xD;
             and/or TP antibodies at screening.&#xD;
&#xD;
          -  2. Subjects with history of digestive system,urinary system, liver,central nervous&#xD;
             system, blood system, endocrine system,respiratory system,immune system,cardiovascular&#xD;
             system,and/or malignant tumor or others medical conditions (such as history of mental&#xD;
             illness, etc.) that are not suitable for clinical trial participation;Subjects with&#xD;
             history of epilepsy, bipolar disorder/mania, high intraocular pressure, or acute&#xD;
             angular-closure glaucoma.&#xD;
&#xD;
          -  3. Known allergic reactions or hypersensitivity to any excipient of the drug&#xD;
             formulation(s) ,or anaphylaxis physique.&#xD;
&#xD;
          -  4. Use of any prescription or non-prescription medications within 14 days prior to&#xD;
             initial dosing,or Use of any medications known to inhibit or induce cytochrome P&#xD;
             enzyme drug metabolism within 28 days prior to initial dosing.&#xD;
&#xD;
          -  5. Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit&#xD;
             within 48 hours prior to initial dosing.&#xD;
&#xD;
          -  6. Positive results from urine drug screen test.&#xD;
&#xD;
          -  7. History of alcoholism or drink regularly within 3 months prior to the study(defined&#xD;
             as Alcohol consumption of &gt; 21 units/week), or positive results from alcohol breath&#xD;
             test.&#xD;
&#xD;
          -  8. Regular smoking of more than 10 cigarettes per day within 3 months before&#xD;
             administration of study drug.&#xD;
&#xD;
          -  9. Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing.&#xD;
&#xD;
          -  10. Subjects who plan to receive or have had organ transplants.&#xD;
&#xD;
          -  11. Females who are lactating/breastfeeding, or positive result from pregnancy test&#xD;
             for women of child-bearing potential.&#xD;
&#xD;
          -  12. Subjects who participated in another clinical trial within 3 months prior to&#xD;
             initial dosing.&#xD;
&#xD;
          -  13. Any other condition with in the opinion of the investigator would render the&#xD;
             patient unsuitable for inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Xuhui Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

